Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Poziotinib DDI Study with Itraconazole, Phenytoin, and Paroxetine
NCT04981704Phase 1Completed
- Sponsor
- Spectrum Pharmaceuticals, Inc.
- Start
- Apr 2021
- Primary completion
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of poziotinib in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Spectrum Pharmaceuticals, Inc. Primary endpoints: Area Under the Curve of Poziotinib and Metabolites (M1 and M2), Maximum Observed Concentration of Poziotinib and Metabolites (M1 and M2) and 2 more. Started Apr 2021; status: completed.
02
Drugs
poziotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04981704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04981704.